Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Featured trial
A Study to Evaluate the Efficacy, Safety and Tolerability of Combinations Study medication and Mirabegron Compared to Study medication and Mirabegron Monotherapy in the Treatment of Overactive Bladder

A Study to Evaluate the Efficacy, Safety and Tolerability of Combinations Study medication and Mirabegron Compared to Study medication and Mirabegron Monotherapy in the Treatment of Overactive

  • 180 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH). NCT02757768, 178-MA-1008.

The purpose of the study is to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for

incontinence
tamsulosin
mirabegron
lower urinary tract symptoms
  • 204 views
  • 02 Sep, 2021
  • 1 location
Featured trial
SYNERGY

SYNERGY

  • 99 views
  • 08 Nov, 2020
  • 1 location
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and bladder blood flow.

  • 0 views
  • 23 Mar, 2022
  • 1 location
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Research question: A wealth of existing research has established the independent effectiveness of mirabegron and neuromodulation in the treatment of overactive bladder syndrome

  • 0 views
  • 22 Mar, 2022
  • 1 location
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

The purpose of this study is to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluate the safety and tolerability of

incontinence
mirabegron
  • 9 views
  • 13 Jun, 2022
  • 24 locations
Activation of Brown Adipose Tissue Metabolism Using Mirabegron (GB9)

receptor (ADBR3) at higher doses of Mirabegron may be required to elicit changes in glycemia, but should be combined with Beta-1 adrenergic receptor (ADRB1) antagonists to suppress the unwanted effects on

Accepts healthy volunteers
  • 0 views
  • 29 May, 2022
  • 1 location
Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)

stimulation (PTNS) and mirabegron treatment versus PTNS with placebo on change in the number of UUI episodes over a 12-week treatment course. Secondary aims include comparing the efficacy of combined

incontinence
percutaneous tibial nerve stimulation
mirabegron
Accepts healthy volunteers
  • 0 views
  • 15 Dec, 2021
  • 1 location
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research

insulin
body mass index
hemoglobin a1c
Accepts healthy volunteers
  • 0 views
  • 23 Mar, 2022
  • 1 location
Mechanisms for Activation of Beige Adipose Tissue in Humans

Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and

impaired glucose tolerance
Accepts healthy volunteers
fasting
  • 283 views
  • 24 Mar, 2022
  • 1 location